Crizotinib (PF‐02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P‐glycoprotein
Crizotinib (PF‐02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P‐glycoprotein
复制标题
DOI：
10.1111/j.1476-5381.2012.01849.x
复制
发表时间：
2012-07
影响因子：
7.3
通讯作者：
Wenqiang Zhou;Xu Zhang;Chao Cheng;Fang Wang;Xiao-kun Wang;Yong‐ju Liang;K. To;Wang Zhou
中科院分区：
文献类型：
--
作者：
Wenqiang Zhou;Xu Zhang;Chao Cheng;Fang Wang;Xiao-kun Wang;Yong‐ju Liang;K. To;Wang Zhou
除了靶向众所周知的致癌c-Met外，克唑替尼还是第一种在临床试验中抑制间变性淋巴瘤激酶（ALK）的口服酪氨酸激酶抑制剂，用于治疗非小细胞肺癌。在此，我们评估了克唑替尼在体外和体内逆转多药耐药（MDR）的可能性。
Besides targeting the well‐known oncogenic c‐Met, crizotinib is the first oral tyrosine kinase inhibitor inhibiting anaplastic lymphoma kinase (ALK) in clinical trials for the treatment of non‐small cell lung cancer. Here, we assessed the possible reversal of multidrug resistance (MDR) by crizotinib in vitro and in vivo.